Matching slides 303,780
Current window 200,041-200,070
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

200,041-200,070 of 303,780

filter-aware
04
The slide uses a hybrid structure combining a process/value chain flow with data tables and descriptive lists.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Rising Success1 hit
07
The slide uses a numbered list format (01, 02, 03) to structure the key takeaways about the partner company MOMA.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Rising Success1 hit
10
The slide uses a vertical timeline structure to detail specific partnership deals and their associated site/charging point commitments.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
11
Allego | Results Presentation Deck | 22 slidesAllego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · The Breakthrough1 hit
12
The slide uses a split layout with charts on the left and key takeaways on the right.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · The Breakthrough1 hit
13
The slide uses a two-column layout: left side presents quantitative growth metrics (bar charts), right side presents qualitative strategic takeaways.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · The Breakthrough1 hit
14
The slide uses a split layout: a line chart on the left and a numbered list of strategic actions on the right.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · The Breakthrough1 hit
15
Allego | Results Presentation Deck | 22 slidesAllego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · The Breakthrough1 hit
16
The slide uses a waterfall-like progression to show growth in charging ports.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · The Breakthrough1 hit
17
The slide uses a mix of metrics and partner logos to validate the company's financing strategy.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Ultimate AchievementLoop · Quick Win Big Bet1 hit
18
Utilization rate calculation note provided in footer.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Ultimate AchievementLoop · Quick Win Big Bet1 hit
20
Allego | Results Presentation Deck | 22 slidesAllego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
21
The table provides a detailed breakdown of adjustments to reconcile IFRS loss to non-IFRS metrics like EBITDA and Free Cash Flow.Allego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
22
Allego | Results Presentation Deck | 22 slidesAllego | Results Presentation Deck | 22 slides · Allego
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
01
Slide 1
The slide uses a global map background and patient portraits to emphasize the scope and human impact of the company's mission.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
02
AN2 Therapeutics | Investor Presentation Deck | 25 slidesAN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
03
AN2 Therapeutics | Investor Presentation Deck | 25 slidesAN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
07
AN2 Therapeutics | Investor Presentation Deck | 25 slidesAN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
08
AN2 Therapeutics | Investor Presentation Deck | 25 slidesAN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Uses a nested Venn/funnel diagram to illustrate market segmentation.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide uses a two-part table structure to contrast standard care with refractory care, emphasizing toxicity and lack of FDA approval for many agents.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide presents a balanced view, showing both efficacy and significant safety/tolerability concerns for the competitor drug.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
12
Scientific illustration showing molecular binding interaction.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
13
EBO = Epetraborole; MAC = Mycobacterium avium complex; MIC = Minimum Inhibitory Concentration.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The chart demonstrates dose-dependent efficacy of Epetraborole (EBO) against M. avium 2285 (R).AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
The charts demonstrate dose-dependent efficacy and synergy between EBO and SoC.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
17
The slide highlights the therapeutic potential of the drug by showing superior accumulation at the site of infection.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
18
The slide outlines a seamless transition between Phase 2 and Phase 3 trials for a specific drug candidate.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
19
Uses a funnel-like diagram to represent market segments.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Business Model1 hit
20
The table uses checkmarks and X marks to denote performance against specific clinical criteria.AN2 Therapeutics | Investor Presentation Deck | 25 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Business Model1 hit